By	O
inhibiting	O
IL-1α	O
AAA	O
BBB/IL-1β	O
competitively	O
from	O
binding	O
to	O
the	O
IL-1	O
type-I	O
receptor	O
,	O
anakinra	O
,	O
neutralizes	O
the	O
activity	O
that	O
pertains	O
to	O
these	O
key	O
mediators	O
of	O
autoinflammatory	O
and/or	O
immune	O
processes	O
.	O

Clinical	O
outcomes	O
of	O
those	O
who	O
use	O
an	O
ACE	O
inhibitor	O
(	O
ACEI	O
)	O
or	O
angiotensin	O
II	O
type-I	O
receptor	O
blocker	O
(	O
ARB	O
)	O
were	O
comparable	O
with	O
those	O
of	O
patients	O
who	O
do	O
not	O
use	O
ACEI/ARB	O
among	O
COVID-19	B
patients	O
with	O
diabetes	B
and	O
hypertension	B
.	O

Patients	O
taking	O
angiotensin-converting	O
enzyme	O
inhibitors/angiotensin	O
II	O
type	O
I	O
receptor	O
blockers	O
:	O
higher	O
risks	O
of	O
severe	B
acute	I
respiratory	I
syndrome	I
coronavirus	I
2	I
infection	B
$	O
but	O
milder	O
clinical	O
manifestations	O
?	O

Avoiding	O
the	O
prescription	O
of	O
non-steroidal	O
anti-inflammatory	O
drugs	O
,	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
,	O
or	O
angiotensin	O
II	O
type	O
I	O
receptor	O
blockers	O
is	O
advised	O
for	O
COVID-19	B
AAA	I
BB	I
CCC	I
patients	O
.	O

